In a German real-world prospective study, 261 patients with advanced/metastatic HER2-positive breast cancer continued TBP (for more than 1 month) after first-line trastuzumab therapy and 157 patients discontinued (discontinuation within 30 days) [10]. The gene discussed is ERBB2; the disease is breast cancer.